Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Clinical trial NCT02185560 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02185560
- Sponsor
- Bayer
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2014-06-27
- Primary completion
- 2020-02-27
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.